Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer

Ana Oaknin , Anna Tinker , Lucy Gilbert , Vanessa Samouëlian , Cara Mathews , Jubilee Brown , Maria-Pilar Barretina-Ginesta , Victor Moreno , Adriano Gravina , Cyril Abdeddaim , Susana Banerjee , Wei Guo , Hadi Danaee , Ellie Im , Renaud Sabatier (1, 2, 3)

1 Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, 13009 Marseille, France.
2 IPC - Institut Paoli-Calmettes
3 CRCM - Centre de Recherche en Cancérologie de Marseille

Domaines: Cancer

Ana Oaknin, Anna Tinker, Lucy Gilbert, Vanessa Samouëlian, Cara Mathews, et al.. Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer. JAMA oncology, 2020, 6 (11), pp.1766. ⟨10.1001/jamaoncol.2020.4515⟩. ⟨hal-03622783⟩